UK study of 451,606 hospitalized patients reveals systemic glucocorticoid use associated with 2.6-fold increased risk of new-onset diabetes, with incidence rates of 51.9 vs 18.5 per 100 person-years in exposed vs unexposed groups.
Patients on 300 mg of sulthiame saw a nearly 40% reduction in apnea episodes in just 12 weeks, offering a promising new drug treatment for obstructive sleep apnea.
Nocturnal hot flashes are more frequent after midnight, with more than half occurring in the second half of the night, potentially disrupting REM sleep and contributing to heightened cardiovascular disease risk in perimenopausal women.
Patients with type 2 diabetes may face an 83% higher risk of developing asthma, while patients with asthma are 28% more likely to develop diabetes, revealing a bidirectional relationship.
For each unit increase in insulin resistance, the risk of pancreatitis rose by 31%, the risk of sleep disorders by 18%, and the risk of bacterial infections by 8%.